Literature DB >> 24902555

Adherence to treatment and supervision for tuberculosis in a DOTS programme among pastoralists in Uganda.

J Kisambu1, F Nuwaha2, J N Sekandi2.   

Abstract

OBJECTIVE: To estimate the levels of adherence to anti-tuberculosis medications and associated risk factors in a pastoral community practising transhumance in North-Eastern Uganda.
DESIGN: A cross-sectional retrospective study of a cohort of tuberculosis (TB) patients and their community volunteers registered from August 2008 to July 2009. Self-reported data were collected on doses missed, doses not supervised, sociodemographic situation, drug availability, perceived drug side effects and use of the directly observed treatment (DOT) card. Medication adherence was defined as having ingested at least 90% of doses given, and supervision adherence was defined as direct observation of at least 90% of doses ingested. Independent predictors of medication adherence were identified using binary and multivariate logistic regression.
RESULTS: A total of 126 TB patients and an equal number of community volunteers were enrolled in the study. Medication and supervision adherence were estimated at respectively 72% and 63%. Independent predictors of medication adherence were perceived drug side effects (adjusted odds ratio [aOR] 5.0, 95%CI 1.86-13.6), running out of drugs (aOR 5.97, 95%CI 2.27-15.70) and DOT card not filled in (aOR 6.65, 95%CI 2.08-20.66).
CONCLUSION: Adherence among pastoralists is less than optimal due to poor institutionalisation of the DOTS strategy in a pastoralist community.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24902555     DOI: 10.5588/ijtld.13.0753

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Comparison of tuberculosis treatment outcomes by method of treatment supervision in the Fiji Islands.

Authors:  N Narayan; K Viney; S Varman
Journal:  Public Health Action       Date:  2014-09-21

2.  Factors Associated with Retention to Care in an HIV Clinic in Gabon, Central Africa.

Authors:  Saskia Janssen; Rosanne Willemijn Wieten; Sebastiaan Stolp; Anne Lia Cremers; Elie Gide Rossatanga; Kerstin Klipstein-Grobusch; Sabine Belard; Martin Peter Grobusch
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

3.  Patient attitudes towards community-based tuberculosis DOT and adherence to treatment in an urban setting; Kampala, Uganda.

Authors:  Sempeera Hassard; Anguzu Ronald; Kawooya Angella
Journal:  Pan Afr Med J       Date:  2017-05-01

4.  Health services uptake among nomadic pastoralist populations in Africa: A systematic review of the literature.

Authors:  Victoria M Gammino; Michael R Diaz; Sarah W Pallas; Abigail R Greenleaf; Molly R Kurnit
Journal:  PLoS Negl Trop Dis       Date:  2020-07-27

5.  APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study.

Authors:  Junke Qiu; Caihong Wang; Xiaohong Pan; Lei Pan; Xiaoqing Huang; Jiekun Xu; Xiaobo Ji; Minjie Mao
Journal:  BMC Infect Dis       Date:  2019-02-04       Impact factor: 3.090

6.  Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study.

Authors:  Paul Yonga; Stephen Kalya; Lutgarde Lynen; Tom Decroo
Journal:  Int Health       Date:  2020-02-12       Impact factor: 2.473

7.  Is directly observed tuberculosis treatment strategy patient-centered? A mixed method study in Addis Ababa, Ethiopia.

Authors:  Belete Getahun; Zethu Zerish Nkosi
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

8.  Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study.

Authors:  Juliet N Sekandi; Esther Buregyeya; Sarah Zalwango; Kevin K Dobbin; Lynn Atuyambe; Damalie Nakkonde; Julius Turinawe; Emma G Tucker; Shade Olowookere; Stavia Turyahabwe; Richard S Garfein
Journal:  ERJ Open Res       Date:  2020-04-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.